Sera Prognostics, Inc. (SERA) NASDAQ
2.13
+0.14(+7.04%)
Currency In USD
- General
- Statistics
- Historical Data
- Profile
- Financials
2.13
+0.14(+7.04%)
Currency In USD
Address
2749 East Parleys Way
Salt Lake City, UT 84109
United States of America (the)
Phone
801 990 0520
Website
Sector
Healthcare
Industry
Medical - Diagnostics & Research
Employees
63
First IPO Date
July 15, 2021
| Name | Title | Pay | Year Born |
| Evguenia Lindgardt | President, Chief Executive Officer & Director | 693,398 | 1975 |
| Zhenya Lindgardt | President, Chief Executive Officer & Director | 693,398 | 1974 |
| Gregory C. Critchfield | Executive Director | 19,904 | 1953 |
| Austin Aerts | Chief Financial Officer | 367,625 | 1988 |
| Robert G. Harrison | Chief Information Officer | 384,178 | 1966 |
| Benjamin G. Jackson | General Counsel | 410,755 | 1979 |
| John J. Boniface | Chief Scientific Officer | 431,282 | 1962 |
| Paul Kearney | Chief Data Officer | 468,734 | 1968 |
| Tiffany Inglis | Chief Medical Officer | 575,549 | N/A |
| Chuck Hyde | Head of Market Access | 0 | N/A |
| Lee Anderson | Chief Commercial Officer | 0 | N/A |
| Jennifer Zibuda | Head of Investor Relations | 0 | N/A |
Sera Prognostics, Inc., a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in asymptomatic singleton pregnancies. It is also developing a portfolio of product candidates for various pregnancy-related conditions, including preeclampsia, molecular time-to-birth, gestational diabetes mellitus, fetal growth restriction, stillbirth, and postpartum depression. The company was incorporated in 2008 and is headquartered in Salt Lake City, Utah.